Download Free Medical The Impact of COVID-19 on Cancer Treatment in Japan PowerPoint Presentation

The Impact of COVID-19 on Cancer Treatment in Japan PowerPoint Presentation

DOWNLOAD MEDICAL POWERPOINT PRESENTATION

About This Presentation

Description : This report titled, “The Impact of COVID-19 on Cancer Treatment in Japan” is by the IQVIA Institute and is a voluntary, unpaid, IQVIA-sponsored survey of Oncologists, Hem-oncologists and Onco-surgeons examining the impact of coronavirus COVID-19 on cancer treatment in Japan.

Tags : Healthcare, Oncology, cancer, Cancer Treatment, COVID-19, Japan, Oncologists, Hem-oncologists, Onco-surgeons

Published on : Jul 20, 2020 | Views : 1976 | Downloads : 0

Shareable Url :

Embed Code :

Comment

Transcript

Slide 1-

© 2020. All rights reserved. IQVIA® is a registered trademark of IQVIA Inc. in the United States, the European Union, and various other countries. Japan Report Impact of COVID-19 on Cancer Treatment
Slide 2-

1 Overview What is the purpose of this report? The purpose of this report is to determine if there has been any changes reported in the treatment of cancer across Japan now as restrictions ease and exit lockdown We will be comparing what Onco Specialists are telling us now (Wave 2) vs what they said at the start of the pandemic (Wave 1) The information gathered from IQVIA’s Onco Specialists community provides insight and understanding into key topics such as: The impact of cancer patient visits at different phases during COVID -19 Interaction via telehealth/ remote consultations during difference phases of the pandemic What specific type of treatment practices are impacted? What are the current changes anticipated now that restrictions are being relaxed? What pharma/biotech initiatives can help Onco Specialists deliver the best care possible their patients What communication channels are pharma companies using to communicate with Onco Specialists? How and When was the data collected? A 3mins survey was sent out to Specialists treating 10 or more Cancer patients in Japan These Specialist were paid an honoraria to complete the survey This survey was not sponsored by any IQVIA client/customer. IQVIA was not compensated in any way for this survey Data collection occured from the 17th of June – 22nd of June 2020 (Wave 2) We will be comparing results with our Wave 1 survey that took place between 20th of April – 24th of April 2020 (Wave 1) Impact of COVID-19 on cancer treatment – Japan June 2020. Copyright 2020 IQVIA. All rights reserved.
Slide 3-

Across Japan, 80 Onco Specialists participated in a 3 mins survey Wave 2 (n=80) Sample split *Others include onco-surgeon, gastroenterology surgeons, general surgeons, gastroenterologists, pulmonologists, breast surgeons treating cancer Q0. Which of the following best describes your primary medical specialty? 38% Hematologist 6% Hem-Oncologist 13% Oncologists 11% IMs 23% Others* 10% Urologist Impact of COVID-19 on cancer treatment – Japan June 2020. Copyright 2020 IQVIA. All rights reserved. 2
Slide 4-

Average* number of cancer patients seen prior to COVID-19 outbreak Average number of cancer patients seen per week (Wave 1) Average number of cancer patients seen last week (Wave 2) 40 Patients 18 Patients 24 Patients Pandemic Outburst Exiting Lockdown Q1: After the COVID-19 outbreak, are you seeing fewer hematology/oncology patients per week? Impact of COVID-19 on cancer treatment – Japan June 2020. Copyright 2020 IQVIA. All rights reserved. 3 Wave 2 (n=39) Wave 1 (n=63) Impact on number of cancer patient seen due to COVID 19 outbreak * Weighted average of Wave 1 and Wave 2 Note: All numbers shown in slide are absolute numbers (number of patients) There has been a rise in the number of cancer patients seen per week as restrictions ease in Japan but is still significantly lower than pre COVID days
Slide 5-

Wave 1 Wave 2 Delay in surgeries 30% 50% 47% 35% 33% 31% Less number of referrals to hematologists/ oncologists Delayed chemotherapy Impact of COVID-19 on cancer treatment – Japan June 2020. Copyright 2020 IQVIA. All rights reserved. 4 Q3: What according to you is the impact on cancer treatment practice amidst the COVID-19 crisis? Wave 2 (n=80) Wave 1 (n=120) Impact of COVID 19 crisis on cancer treatment A significant level of improvement was observed vs wave 1 on delay in surgeries and chemotherapies; though patient referrals has a higher impact in wave 2 than wave 1
Slide 6-

Restrictions led to a slight increase in remote consultations (4% to 11%), however with time, Onco Specialists believe this would not have a major practice on their practice 4% Prior to COVID outbreak 11% During lockdown 8% Post lockdown 10% When COVID won’t exist % proportion of patients on remote consultations Q2: Could you please estimate the typical proportion of interaction via telehealth/remote consultation in the following time period? Impact of COVID-19 on cancer treatment – Japan June 2020. Copyright 2020 IQVIA. All rights reserved. 5
Slide 7-

10% Patients Physicians Hospitals Limited visitor policies and increase in remote consultations are some of the key practice changes seen by Onco Specialists with <8% reporting change in treatment schedule to include oral/SC therapies Change in treatment protocol to introduce oral cancer medications Change treatments to include cancer medications which patients can self- administer Addition of more surgery days/ chemo cycles Increased daily working hours Increased frequency of remote consultations Refer patients to other facilities due to lack of hospital infrastructure Allow in-person visits primarily for critical and/or newly diagnosed cancer patients 8% 4% 14% 6% 30% Limited visitor policy except in case of end of life circumstances 84% 31% Q4: What key changes are you currently seeing in your practice setting as we see restrictions being relaxed to some extent now? Impact of COVID-19 on cancer treatment – Japan June 2020. Copyright 2020 IQVIA. All rights reserved. 6
Slide 8-

To maintain social distancing, E-mails, and post/direct mails have become current new modes to connect with Onco Specialists Current modes of communication Physicians’ expectations from pharma companies Q5: What initiatives can pharma/biotech take in order to help you manage increased cancer patients in the coming few months? To increase patient support services 53% 48% Update on the availability of critical oncology drugs for their patients Tips on how to best communicate remotely with the rest of their practice and patients 43% Availability of an online resource center which can be accessed for product related information 60% E-mail 76% 43% 31% Virtual Meetings 30% 24% Messaging app 18% 16% Face to face 13% Post / Direct Mail Phone Call Webinars No Contacts Q6: In the current COVID-19 scenario, which of the following communication channels are pharma companies using to communicate with you? Impact of COVID-19 on cancer treatment – Japan June 2020. Copyright 2020 IQVIA. All rights reserved. 7
Slide 9-

8 DISCLAIMER Sample size is not representative at country level. Sample composition varies at the country level. Sample sizes are different between Wave 1 and Wave 2 – Its important to keep that in mind when making comparisons between the changes observed in responses. In addition, some Oncology specialists might be responding to questions based on what they have actually experienced, whilst others may be based on what they believe might happen. This was a pulse survey. The questions asked are intended to provide top level insight into what Oncology specialists across the country are experiencing. Impact of COVID-19 on cancer treatment – Japan June 2020. Copyright 2020 IQVIA. All rights reserved.
Slide 10-

© 2020. All rights reserved. IQVIA® is a registered trademark of IQVIA Inc. in the United States, the European Union, and various other countries. For further information, please contact: GlobalPI@IQVIA.com

User Presentation
Related Presentations

The Beginning of Human Life and Prevention of Chronic Disease: Reframing the First 1,000 Days

By: docshare
Views: 2929

Wearable Wellness Technology That Improves Your Health and Performance

By: docshare
Views: 2656

Reopening the United States Health System - Tracking the Pandemic, Reopening Readiness

By: docshare
Views: 1515

2019 R&D Achievements New product launches, clinical trial activity, and investments

By: docshare
Views: 1819

Shifts in Healthcare Demand, Delivery, and Care During the COVID-19 Era - Tracking the impact in the United States

By: docshare
Views: 1821

Overview of Cancer Genetics

By: drdwayn
Views: 2441

An Overview of Radiation Therapy for Health Care Professionals

By: drdwayn
Views: 1936

Surgical Management of Metastases

By: VineetaBose
Views: 804

Disorders of the Pancreas

By: JenniferDwayne
Views: 3091

Acute Pancreatitis

By: drdwayn
Views: 8012

docshare

About : I am a passionate medical marketing professional with hands on experience in healthcare digital marketing.
Occupation : Medical Professional
Specialty : Other Health Professionals
Country : India
Website :

HEALTH A TO Z